All lobbying filings

LMH STRATEGIC SOLUTIONS

LMH STRATEGIC SOLUTIONS filed a Q3 report for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA on October 19, 2026, reporting $30,000 in lobbying income.

Lobbying for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Biopharmaceutical industry trade association.

All filings by LMH STRATEGIC SOLUTIONS · Everything PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Income

$30,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 2

SOPHIE KHANAHMADI

Previously held: Legislative Asst., Rep. Martha Roby; Legislative Asst., Rep. Lee Terry; Staff Asst./LC, Senator Jeff Sessions
ALANNA TEMME

Previously held: Legislative Director, U.S. Representative Jon Porter

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Pharmacy

Pharmaceutical Supply Chain. H.R.2213: Medical Supply Chain Resiliency Act. Issues related to the 340(b) program. H.R.1492/S.832: EPIC Act of 2025.

Trade (domestic/foreign)

Issues related to USTR/trade.

Bills named in this filing 3

H.R. 2213
Medical Supply Chain Resiliency Act
H.R. 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
S. 832
EPIC Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.